Lettieri J - Search Results

1

A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.

Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. Weickhardt A, et al. Among authors: lettieri j. J Thorac Oncol. 2012 Feb;7(2):419-26. doi: 10.1097/JTO.0b013e31823c5b11. J Thorac Oncol. 2012. PMID: 22237261 Free PMC article. Clinical Trial.

2

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.

Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D, Mross KB. Schultheis B, et al. Among authors: lettieri j. Ann Oncol. 2013 Jun;24(6):1560-7. doi: 10.1093/annonc/mdt056. Epub 2013 Mar 13. Ann Oncol. 2013. PMID: 23493136 Free PMC article. Clinical Trial.

3

Noise Complaints and Land Rezoning as a Predictor of Hate Crimes in a New York City Borough.

Lettieri J, Logie K, Paccione-Frometa J. Lettieri J, et al. J Interpers Violence. 2023 Jul;38(13-14):8645-8667. doi: 10.1177/08862605231158756. Epub 2023 Mar 13. J Interpers Violence. 2023. PMID: 36915264

4

Exposure-Response Modeling and Simulation of Progression-Free Survival and Adverse Events of Sorafenib Treatment in Patients With Advanced Thyroid Cancer.

Grevel J, Jentsch G, Austin R, Prins NH, Lettieri J, Mitchell D, Huang F, Brose MS, Schlumberger M, Meinhardt G, Peña CEA, Ploeger BA. Grevel J, et al. Among authors: lettieri j. Clin Transl Sci. 2019 Sep;12(5):459-469. doi: 10.1111/cts.12634. Epub 2019 Apr 12. Clin Transl Sci. 2019. PMID: 30920122 Free PMC article. Clinical Trial.

5

Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous Moxifloxacin in Pediatric Patients: Dose Optimization in a Phase 1 Study.

Stass H, Lettieri J, Vanevski KM, Willmann S, James LP, Sullivan JE, Arrieta AC, Bradley JS. Stass H, et al. Among authors: lettieri j. J Clin Pharmacol. 2019 May;59(5):654-667. doi: 10.1002/jcph.1358. Epub 2019 Jan 25. J Clin Pharmacol. 2019. PMID: 30681729 Free PMC article. Clinical Trial.

6

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.

Marmé F, Gomez-Roca C, Graudenz K, Huang F, Lettieri J, Peña C, Trnkova ZJ, Eucker J. Marmé F, et al. Among authors: lettieri j. Cancer Chemother Pharmacol. 2018 Apr;81(4):727-737. doi: 10.1007/s00280-018-3540-9. Epub 2018 Feb 21. Cancer Chemother Pharmacol. 2018. PMID: 29468456 Clinical Trial.

7

Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.

Gerisch M, Hafner FT, Lang D, Radtke M, Diefenbach K, Cleton A, Lettieri J. Gerisch M, et al. Among authors: lettieri j. Cancer Chemother Pharmacol. 2018 Jan;81(1):195-206. doi: 10.1007/s00280-017-3480-9. Epub 2017 Nov 29. Cancer Chemother Pharmacol. 2018. PMID: 29188322 Free PMC article. Clinical Trial.

8

No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.

Huang F, Ajavon A, Huang E, Lettieri J, Liu R, Peña C, Berse M. Huang F, et al. Among authors: lettieri j. Thyroid. 2017 Sep;27(9):1118-1127. doi: 10.1089/thy.2017.0085. Epub 2017 Aug 29. Thyroid. 2017. PMID: 28741453 Free PMC article. Clinical Trial.

9

A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer.

Jones RL, Bendell JC, Smith DC, Diefenbach K, Lettieri J, Boix O, Lockhart AC, O'Bryant C, Moore KN. Jones RL, et al. Among authors: lettieri j. Cancer Chemother Pharmacol. 2015 Oct;76(4):777-84. doi: 10.1007/s00280-015-2827-3. Epub 2015 Aug 18. Cancer Chemother Pharmacol. 2015. PMID: 26281907 Clinical Trial.

10

Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers.

Hellmann MD, Sturm I, Trnkova ZJ, Lettieri J, Diefenbach K, Rizvi NA, Gettinger SN. Hellmann MD, et al. Among authors: lettieri j. Clin Lung Cancer. 2015 Nov;16(6):514-22. doi: 10.1016/j.cllc.2015.04.003. Epub 2015 Apr 20. Clin Lung Cancer. 2015. PMID: 26003007 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

64 results

Search Page